Vor Biopharma (NASDAQ:VOR) Trading 8% Higher – Still a Buy?

Vor Biopharma Inc. (NASDAQ:VOR)’s share price was up 8% on Friday . The company traded as high as $15.76 and last traded at $16.1260. Approximately 188,694 shares were traded during trading, a decline of 81% from the average session volume of 975,209 shares. The stock had previously closed at $14.93.

Wall Street Analysts Forecast Growth

VOR has been the subject of several analyst reports. Weiss Ratings downgraded shares of Vor Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 15th. Jefferies Financial Group raised shares of Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. Wells Fargo & Company assumed coverage on Vor Biopharma in a research report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $31.00 price objective on shares of Vor Biopharma in a research report on Monday, May 18th. Finally, Wedbush lifted their price objective on Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $42.25.

Vor Biopharma Price Performance

The business’s 50 day moving average is $14.77 and its two-hundred day moving average is $14.37.

Vor Biopharma (NASDAQ:VOR) last announced its earnings results on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter. As a group, equities analysts anticipate that Vor Biopharma Inc. will post -2.51 EPS for the current fiscal year.

Insider Activity

In related news, Director Ra Capital Management, L.P. sold 165,150 shares of the company’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $15.77, for a total value of $2,604,415.50. Following the completion of the transaction, the director directly owned 2,402,095 shares in the company, valued at approximately $37,881,038.15. The trade was a 6.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have sold 3,002,903 shares of company stock worth $49,412,176. Insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On Vor Biopharma

A number of large investors have recently added to or reduced their stakes in VOR. China Universal Asset Management Co. Ltd. bought a new stake in Vor Biopharma during the fourth quarter worth about $36,000. Bank of America Corp DE increased its position in shares of Vor Biopharma by 679.3% during the 3rd quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock valued at $232,000 after purchasing an additional 4,144 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of Vor Biopharma during the 3rd quarter valued at about $230,000. BNP Paribas Financial Markets raised its holdings in shares of Vor Biopharma by 497.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after buying an additional 5,058 shares in the last quarter. Finally, Bridgeway Capital Management LLC bought a new stake in Vor Biopharma in the 3rd quarter worth approximately $304,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).